116,347 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Purchased by Fox Hill Wealth Management

Fox Hill Wealth Management acquired a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 116,347 shares of the company’s stock, valued at approximately $2,350,000. Teva Pharmaceutical Industries accounts for approximately 1.1% of Fox Hill Wealth Management’s investment portfolio, making the stock its 28th biggest holding.

Several other large investors have also recently made changes to their positions in TEVA. Howard Bailey Securities LLC boosted its position in shares of Teva Pharmaceutical Industries by 3.5% in the 3rd quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock worth $292,000 after purchasing an additional 494 shares in the last quarter. ASR Vermogensbeheer N.V. raised its stake in Teva Pharmaceutical Industries by 1.6% during the third quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock valued at $645,000 after buying an additional 515 shares during the last quarter. Retirement Planning Co of New England Inc. boosted its holdings in Teva Pharmaceutical Industries by 1.8% in the third quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock worth $671,000 after acquiring an additional 588 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Teva Pharmaceutical Industries by 0.5% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company’s stock worth $1,981,000 after acquiring an additional 615 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Teva Pharmaceutical Industries by 6.1% during the third quarter. Smartleaf Asset Management LLC now owns 10,794 shares of the company’s stock valued at $207,000 after acquiring an additional 624 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Eliyahu Sharon Kalif sold 345,810 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the completion of the sale, the executive vice president owned 57,478 shares of the company’s stock, valued at $1,933,559.92. This represents a 85.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Roberto Mignone sold 77,400 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the transaction, the director owned 367,600 shares in the company, valued at $11,116,224. This trade represents a 17.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 767,870 shares of company stock valued at $23,888,014 in the last 90 days. Insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

TEVA has been the topic of a number of analyst reports. The Goldman Sachs Group upped their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Scotiabank upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $37.56.

Teva Pharmaceutical Industries Stock Down 4.3%

Shares of Teva Pharmaceutical Industries stock opened at $32.31 on Wednesday. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The company’s 50 day moving average is $33.01 and its 200 day moving average is $26.02. The company has a market cap of $37.15 billion, a price-to-earnings ratio of 26.93, a price-to-earnings-growth ratio of 11.30 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.